Review
Open access
Oct 2026
Pembrolizumab plus lenvatinib in the treatment of unresectable cutaneous angiosarcoma: a study protocol of multicentre, open-label phase II study (NCCH2213, PLAS)
Abstract Introduction Cutaneous angiosarcoma (cAS) is a rare and aggressive malignancy with a poor prognosis. The disease most commonly occurs in older adults, with a peak age of 79–85 years and its incidence is expected to increase with population ageing. Standard treatments include radical surgery, radiation therapy,...
D. Ogata, E. Nakano, N. Yamazaki et al.
· BMJ Open · 0 citations